Start532523 • BOM
add
Biocon Ltd
Seneste lukkekurs
323,15 ₹
Dagsinterval
322,45 ₹ - 332,30 ₹
Årsinterval
231,35 ₹ - 395,65 ₹
Markedsværdi
396,60 mia. INR
Gns. volumen
170,80 t
P/E-værdi
27,55
Udbytteprocent
0,15 %
Primær børs
NSE
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(INR) | sep. 2024info | År til år-ændring |
---|---|---|
Indtægt | 35,90 mia. | 3,70 % |
Driftsudgifter | 21,42 mia. | 8,03 % |
Nettoindtægt | -160,00 mio. | -112,74 % |
Overskudsgrad | -0,45 | -112,40 % |
Earnings per share | -0,19 | -115,53 % |
EBITDA | 6,78 mia. | -6,58 % |
Effektiv afgiftssats | 72,46 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(INR) | sep. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 26,50 mia. | -30,00 % |
Samlede aktiver | 571,28 mia. | 4,67 % |
Samlede passiver | 304,08 mia. | 0,36 % |
Samlet egenkapital | 267,20 mia. | — |
Shares outstanding | 1,23 mia. | — |
Kurs/indre værdi | 1,89 | — |
Afkast af aktiver | — | — |
Afkast af kapital | 1,56 % | — |
Pengestrøm
Nettoændring i likviditet
(INR) | sep. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | -160,00 mio. | -112,74 % |
Pengestrøm fra drift | — | — |
Pengestrøm fra investering | — | — |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | — | — |
Fri pengestrøm | — | — |
Om
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Administrerende direktør
Grundlagt
1978
Hovedkvarter
Website
Ansatte
16.315